Diminishing GSH-Adduct Formation of Tricyclic Diazepine-basedMutant IDH1 InhibitorsACS MEDICINAL CHEMISTRY LETTERSIF42022-03-283OA
Discovery of MK-4688: an Efficient Inhibitor of the HDM2-p53 Protein-Protein InteractionJOURNAL OF MEDICINAL CHEMISTRYIF6.82021-10-2919PREAI
Discovery of Novel 3,3-Disubstituted Piperidines as Orally Bioavailable, Potent, and Efficacious HDM2-p53 InhibitorsACS MEDICINAL CHEMISTRY LETTERSIF42016-01-2516OA
Pivotal Role of an Aliphatic Side Chain in the Development of an HDM2 InhibitorACS MEDICINAL CHEMISTRY LETTERSIF42014-02-2720OAAI
Discovery of a novel HDM2 inhibitor with potent in vivo anti-tumor activityCANCER RESEARCHIF16.62012-04-010PRE
Cyclic Sulfones as Novel P3-Caps for Hepatitis C Virus NS3/4A (HCV NS3/4A) Protease Inhibitors: Synthesis and Evaluation of Inhibitors with Improved Potency and Pharmacokinetic ProfilesJOURNAL OF MEDICINAL CHEMISTRYIF6.82010-03-1955OA
Discovery of potent sulfonamide P4-capped ketoamide second generation inhibitors of hepatitis C virus NS3 serine protease with favorable pharmacokinetic profiles in preclinical speciesBIOORGANIC & MEDICINAL CHEMISTRYIF32010-03-0123PRE
Discovery of Narlaprevir (SCH 900518): A Potent, Second Generation HCV NS3 Serine Protease InhibitorACS MEDICINAL CHEMISTRY LETTERSIF42010-02-1586OA
Discovery of novel P3 sulfonamide-capped inhibitors of HCV NS3 protease. Inhibitors with improved cellular potenciesBIOORGANIC & MEDICINAL CHEMISTRYIF32009-07-0115PRE
Toward the Back-Up of Boceprevir (SCH 503034): Discovery of New Extended P4-Capped Ketoamide Inhibitors of Hepatitis C Virus NS3 Serine Protease with Improved Potency and Pharmacokinetic ProfilesJOURNAL OF MEDICINAL CHEMISTRYIF6.82009-05-2026PREAI
Toward Second Generation Hepatitis C Virus NS3 Serine Protease Inhibitors: Discovery of Novel P4 Modified Analogues with Improved Potency and Pharmacokinetic ProfileJOURNAL OF MEDICINAL CHEMISTRYIF6.82009-04-1622PREAI
Second-Generation Highly Potent and Selective Inhibitors of the Hepatitis C Virus NS3 Serine ProteaseJOURNAL OF MEDICINAL CHEMISTRYIF6.82009-02-0540PRE
Design, Synthesis, and Evaluation of Oxygen-Containing Macrocyclic Peptidomimetics as Inhibitors of HCV NS3 ProteaseJOURNAL OF MEDICINAL CHEMISTRYIF6.82009-01-2024PREAI
Discovery and Structure-Activity Relationship of P1-P3 Ketoamide Derived Macrocyclic Inhibitors of Hepatitis C Virus NS3 ProteaseJOURNAL OF MEDICINAL CHEMISTRYIF6.82008-12-2249PREAI
Correlation between PAMPA permeability and cellular activities of hepatitis C virus protease inhibitorsBIOCHEMICAL PHARMACOLOGYIF5.62008-03-0131PREAI
Discovery of the HCVNS3/4A protease inhibitor (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (Sch 503034) II.: Key steps in structure-based optimizationJOURNAL OF MEDICINAL CHEMISTRYIF6.82007-04-20110PREAI
Computational study of the effects of mutations A156T, D168V, and D168Q on the binding of HCV protease inhibitorsJOURNAL OF CHEMICAL THEORY AND COMPUTATIONIF5.52006-09-2123PREAI
Discovery of (1R, 5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor:: A potential therapeutic agent for the treatment of hepatitis C infectionJOURNAL OF MEDICINAL CHEMISTRYIF6.82006-09-07265PREAI
5-endo-trig radical cyclizations of bromomethyldimethylsilyl diisopropylpropargylic ethers.: A highly diastereoselective access to functionalized cyclopentanesJOURNAL OF ORGANIC CHEMISTRYIF3.61999-06-0660PREAI
Study of a radical cyclizations cascade leading to bicyclo[3.1.1]heptanesJOURNAL OF ORGANIC CHEMISTRYIF3.61999-01-1242PREAI
个人简介
教育背景
工作经历
荣誉奖项
未登录.png){kind=icon}
未登录个人简介教育背景工作经历荣誉奖项